Neuron23 Raises $96.5M in Series D Financing

| Posted on |

Here’s a summary based on the information provided:

Neuron23 Overview

  • Startup Name: Neuron23
  • Founded: 2018
  • Location: San Francisco, CA
  • Website: neuron23.com

Fundraising Details

  • Funding Series: Series D
  • Amount Raised: $96.5M
  • Date: June 25, 2025

Investors

  1. Lead Investor: (not specified)
  2. Other Investors:
    • Westlake Village BioPartners
    • SoftBank Vision Fund 2
    • Redmile Group
    • Blue Owl
    • Kleiner Perkins
    • HBM Healthcare Investments (Cayman) Ltd.
    • Acorn Bioventures

Founders and Leadership

  • CEO: Nancy Stagliano

Purpose of Funds

  • The funds will be used to expand operations and enhance R&D efforts.

Additional Information

  • Neuron23 focuses on precision medicines for genetically defined neurological and immunological diseases, emphasizing neurodegenerative, neuroinflammatory, and autoimmune diseases.
  • The company is conducting a Phase 2 clinical trial for NEU-411, targeting early Parkinson’s disease.

Feel free to ask if you need more details!

Source link

2025-06-25 09:05:18